Efficacy Analysis of Trastuzumab Combined With FLOT as Neoadjuvant Treatment of Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric Cancer
نویسندگان
چکیده
This research aims to assess the efficacy of neoadjuvant trastuzumab with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel for treatment human epidermal growth factor receptor 2 positive metastatic gastric cancer. To conduct research, we recruited 80 patients having advanced cancers between January 2020 December 2021 admitted our institution randomly allocated them control observation groups, each 40 cases. Patients in group served as controls, while those underwent a combination docetaxel. The short-term curative outcome after therapy was evaluated; levels carcinoembryonic antigen, serum glycoprotein 19-9 (carcinoembryonic antigen 72-4) were measured by chemiluminescence immunoassay. Side effects experienced both groups recorded when they occurred during therapy. disease rate objective response found be statistically clinically higher than (p<0.05), per findings effectiveness assessment. After treatment, there notable reduction 72-4 (both p<0.05) 72-4, considerably lower (p<0.05). There no evident difference two patient adverse reactions. Trastuzumab combined has high safety 2-positive cancer it can popularized applied new model clinical treatment.
منابع مشابه
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis
Advanced or metastatic breast cancer is an incurable disease with high mortality rate worldwide and about 20% of breast cancers overexpress and amplify the human epidermal growth factor receptor 2 (HER2). Achievements in targeted therapy have benefited people during the past decades. Trastuzumab emtansine (T-DM1), a novel antibody-drug conjugate playing a powerful role in anti-tumor activity, n...
متن کاملLapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials
The purpose of the present study was to quantify the cumulative randomized evidence for the efficacy and safety of lapatinib combined with neoadjuvant therapy in human epidermal growth factor receptor (HER) 2-positive breast cancer. Three electronic databases, MEDLINE, Embase and Cochrane Central Register of Controlled Trials, and the abstracts of major international conferences between incepti...
متن کاملTumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment
BACKGROUND Image texture analysis is a noninvasive technique for quantifying intratumoral heterogeneity, with derived texture features reported to be closely related to the treatment outcome of tumors. Gastric cancer is one of the most common tumors and the third leading cause of cancer-related deaths worldwide. Although trastuzumab is associated with a survival gain among patients with human e...
متن کاملNeoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
PURPOSE We analyzed the responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (NAC) and NAC combined with neoadjuvant human epidermal growth factor receptor-2 (HER2) targeted therapy (NCHTT). METHODS We retrospectively reviewed 59 patients with HER2 amplified locally advanced breast cancer among patients who were treated surgically after neoadjuvant therapy at ...
متن کاملCorrelation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
There is currently no clinical data regarding the efficacy of trastuzumab treatment for the progression of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) occurring during trastuzumab-based chemotherapy. The aim of this study was to retrospectively examine the clinical benefits of trastuzumab for HER2-positive AGC patients who progressed during first-line ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Pharmaceutical Sciences
سال: 2022
ISSN: ['0250-474X', '1998-3743']
DOI: https://doi.org/10.36468/pharmaceutical-sciences.spl.596